xml: <clinical_study>
    <!-- This xml conforms to an XML Schema at:
      https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
    <required_header>
      <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
      <link_text>Link to the current ClinicalTrials.gov record.</link_text>
      <url>https://clinicaltrials.gov/ct2/show/NCT06034405</url>
    </required_header>
    <id_info>
      <org_study_id>AAAU4704</org_study_id>
      <nct_id>NCT06034405</nct_id>
    </id_info>
    <brief_title>Analysis of Lumbar Spine Stenosis Specimens for Identification of Transthyretin Cardiac Amyloidosis</brief_title>
    <official_title>Analysis of Lumbar Spine Stenosis Specimens for Identification of Transthyretin Cardiac Amyloidosis</official_title>
    <sponsors>
      <lead_sponsor>
        <agency>Columbia University</agency>
        <agency_class>Other</agency_class>
      </lead_sponsor>
      <collaborator>
        <agency>National Institute on Aging (NIA)</agency>
        <agency_class>NIH</agency_class>
      </collaborator>
    </sponsors>
    <source>Columbia University</source>
    <oversight_info>
      <has_dmc>Yes</has_dmc>
      <is_fda_regulated_drug>No</is_fda_regulated_drug>
      <is_fda_regulated_device>No</is_fda_regulated_device>
    </oversight_info>
    <brief_summary>
      <textblock>
        Primary objective:&#xD;
  &#xD;
        To identify older adults with transthyretin cardiac amyloidosis (ATTR-CA) early in the course&#xD;
        of the illness, at a time when disease modifying therapies are most effective.&#xD;
  &#xD;
        The specific aims of this epidemiologic investigation include:&#xD;
  &#xD;
          1. To identify subjects with previous lumbar spinal stenosis (LSS) Surgery who have&#xD;
             evidence of transthyretin (TTR) amyloid deposits in spinal specimens and could be at&#xD;
             risk for ATTR cardiac amyloidosis.&#xD;
  &#xD;
          2. To evaluate for ATTR-CA among those with localized TTR in the spinal tissue.&#xD;
  &#xD;
        The study will also explore the following:&#xD;
  &#xD;
          1. The prevalence of amyloid in lumbar spinal stenosis specimens by Congo Red staining.&#xD;
  &#xD;
          2. The prevalence of TTR deposits among subjects with amyloid as determined by mass&#xD;
             spectrometry.&#xD;
  &#xD;
          3. Evaluation of a novel artificial intelligence technique for that can identify amyloid&#xD;
             histologically with standard H&amp;E staining.&#xD;
  &#xD;
          4. Difference in ATTR-CA prevalence between subjects with TTR and indeterminate amyloid&#xD;
             deposits in subject's spine by myocardial uptake of technetium pyrophosphate scan&#xD;
             (Tc99-PYP).&#xD;
      </textblock>
    </brief_summary>
    <detailed_description>
      <textblock>
        This is a multicenter, prospective cohort study aimed at facilitating identification of&#xD;
        individuals with ATTR-CA. Investigators will identify subjects with previous LSS surgery who&#xD;
        have evidence of TTR amyloid deposits in spinal specimens. Subjects with localized TTR in&#xD;
        spinal tissue will be invited to an on-site visit and be evaluated for the presence of&#xD;
        clinical manifestations of ATTR cardiac amyloidosis (ATTR-CA).&#xD;
  &#xD;
        Subjects will undergo nuclear scintigraphy, TTR genetic test, a clinical evaluation,&#xD;
        electrocardiogram, and echocardiogram. Quality of life questionnaires will also be&#xD;
        administered. Subjects who have myocardial retention of the imaging radiotracer with a&#xD;
        Perugini score equal to 2 (uptake equal to bone) or 3 (uptake greater than bone) and&#xD;
        confirmation by SPECT or SPECT/CT that the uptake is myocardial in nature and have no&#xD;
        evidence of monoclonal proteins will be diagnosed with ATTR-CA.&#xD;
  &#xD;
        This study is to be conducted at five study sites: Boston Medical Center, Cedars Sinai&#xD;
        Medical Center, Cleveland Clinic, Columbia University Irving Medical Center, and Tufts&#xD;
        University Medical Center. The Mayo Clinic will serve a Pathology research core to analyze&#xD;
        spine specimens.&#xD;
  &#xD;
        Most of the subjects are expected to complete all the study procedures and questionnaires on&#xD;
        a single day.&#xD;
  &#xD;
        Up to 1663 patients will be consented in this study to have spinal specimens examined for the&#xD;
        presence of amyloid by Congo Red at the Mayo Clinic core lab. From the pool of subjects with&#xD;
        amyloid detected (which anticipate will be 33% or at least 544), the investigators expect to&#xD;
        recruit 163 participants to undergo cardiac phenotyping (Tc99m and cardiac evaluation). Among&#xD;
        the 163 participants who undergo cardiac phenotyping, 98 will have TTR as the precursor&#xD;
        protein identified by mass spectrometry and 65 will have an indeterminant precursor protein&#xD;
        by mass spectrometry.&#xD;
      </textblock>
    </detailed_description>
    <overall_status>Not yet recruiting</overall_status>
    <start_date type="Anticipated">September 2023</start_date>
    <completion_date type="Anticipated">May 2028</completion_date>
    <primary_completion_date type="Anticipated">May 2025</primary_completion_date>
    <study_type>Observational</study_type>
    <has_expanded_access>No</has_expanded_access>
    <study_design_info>
      <observational_model>Cohort</observational_model>
      <time_perspective>Prospective</time_perspective>
    </study_design_info>
    <primary_outcome>
      <measure>Percent of subjects with previous LSS surgery who have evidence of TTR amyloid deposits in their spinal specimen and could be at risk for ATTR cardiac amyloidosis</measure>
      <time_frame>up to 3 years</time_frame>
      <description>To identify who can be at risk for ATTR Cardiac Amyloidosis. The investigator is going to collect spinal ligamentum flavum specimens and stain with congo red and those who result positive for ATTR amyloid in their spinal specimen will be counted</description>
    </primary_outcome>
    <secondary_outcome>
      <measure>Percent of subjects with ATTR-CA among those with localized TTR in their spinal tissue</measure>
      <time_frame>up to 6 years</time_frame>
      <description>To evaluate number of subjects with ATTR-CA among those with localized TTR in their spinal tissue. The investigator is going to perform standard of care (SOC) cardiac amyloidosis work up including PYP scan to confirm cardiac phenotype</description>
    </secondary_outcome>
    <number_of_groups>2</number_of_groups>
    <enrollment type="Anticipated">1663</enrollment>
    <condition>Lumbar Spinal Stenosis</condition>
    <condition>Cardiac Amyloidosis</condition>
    <condition>ATTR Amyloidosis Wild Type</condition>
    <condition>ATTR Gene Mutation</condition>
    <condition>ATTRV122I Amyloidosis</condition>
    <condition>Cardiomyopathy, Hypertrophic</condition>
    <arm_group>
      <arm_group_label>ATTR Negative</arm_group_label>
      <description>Participants who have undergone previous lumbar spinal, and/or carpel tunnel surgery will provide medical record data and spinal specimen for analysis of presence of ATTR amyloid.</description>
    </arm_group>
    <arm_group>
      <arm_group_label>ATTR Positive</arm_group_label>
      <description>Participants who have undergone previous lumbar spinal, and/or carpel tunnel surgery will provide medical record data, spinal specimen, prospective data from cardiac workup with confirmed ATTR amyloid in spinal specimen then undergo cardiac workup for cardiac phenotyping/genotyping.</description>
    </arm_group>
    <intervention>
      <intervention_type>Diagnostic Test</intervention_type>
      <intervention_name>Tc99-PYP or Tc99-HDMP Scan</intervention_name>
      <description>Difference in ATTR-CA prevalence between subjects with TTR and indeterminate amyloid deposits in their spine by myocardial uptake of Tc99-PYP.</description>
      <arm_group_label>ATTR Positive</arm_group_label>
    </intervention>
    <biospec_retention>Samples With DNA</biospec_retention>
    <biospec_descr>
      <textblock>
        Blood will be drawn and analyzed for standard chemistry (Chem-7), liver function tests,&#xD;
        NT-proBNP, troponin I and T, and TTR gene sequencing (see below). For subjects with ATTR-CA&#xD;
        by positive uptake of 99mTc-PYP, further testing of prealbumin and monoclonal proteins (serum&#xD;
        free light chains and immunofixation in serum and urine) will be performed. Additional&#xD;
        aliquots will be stored at -80° for future analysis.&#xD;
      </textblock>
    </biospec_descr>
    <eligibility>
      <study_pop>
        <textblock>
          Previously procured surgical specimens from spinal surgery performed 5 to 15 years ago.&#xD;
        </textblock>
      </study_pop>
      <sampling_method>Probability Sample</sampling_method>
      <criteria>
        <textblock>
          Inclusion Criteria:&#xD;
  &#xD;
            1. Clinically indicated lumbar spinal decompressive surgery that involved removal of the&#xD;
               ligamentum flavum 5 to 15 years prior to enrollment.&#xD;
  &#xD;
            2. Age &gt;60 years at the time of the surgery.&#xD;
  &#xD;
            3. Able to understand and sign the informed consent document after the nature of the&#xD;
               study has been fully explained.&#xD;
  &#xD;
          Exclusion Criteria:&#xD;
  &#xD;
            1. Confirmed primary amyloidosis (AL) or secondary amyloidosis (AA).&#xD;
  &#xD;
            2. Known TTR amyloidosis.&#xD;
  &#xD;
            3. Lumbar surgery for indications other than spinal stenosis.&#xD;
  &#xD;
            4. Active malignancy.&#xD;
  &#xD;
            5. Impairment from stroke, injury or other medical disorder that precludes participation&#xD;
               in the study.&#xD;
  &#xD;
            6. Disabling dementia or other mental or behavioral disease.&#xD;
  &#xD;
            7. Enrollment in a clinical trial not approved for co-enrollment.&#xD;
  &#xD;
            8. Weight &gt;350 lbs.&#xD;
  &#xD;
            9. Inability or unwillingness to comply with the study requirements.&#xD;
  &#xD;
           10. Nursing home resident.&#xD;
  &#xD;
           11. Other reason that would make the subject inappropriate for entry into this study.&#xD;
        </textblock>
      </criteria>
      <gender>All</gender>
      <minimum_age>60 Years</minimum_age>
      <maximum_age>N/A</maximum_age>
      <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
    </eligibility>
    <overall_official>
      <last_name>Mathew S Maurer, MD</last_name>
      <role>Principal Investigator</role>
      <affiliation>Columbia University</affiliation>
    </overall_official>
    <overall_contact>
      <last_name>Mathew S Maurer, MD</last_name>
      <phone>212-932-4537</phone>
      <email>msm10@cumc.columbia.edu</email>
    </overall_contact>
    <overall_contact_backup>
      <last_name>Samantha L Guadalupe, MHA</last_name>
      <phone>212-932-4537</phone>
      <email>slg2172@cumc.columbia.edu</email>
    </overall_contact_backup>
    <location>
      <facility>
        <name>Cedars-Sinai Medical Center</name>
        <address>
          <city>Beverly Hills</city>
          <state>California</state>
          <zip>90211</zip>
          <country>United States</country>
        </address>
      </facility>
      <contact>
        <last_name>Shruti Shantharam</last_name>
        <phone>310-248-8365</phone>
        <email>shruti.shantharam@csmns.org</email>
      </contact>
      <contact_backup>
        <last_name>Christine Sumbi</last_name>
        <phone>310-248-8327</phone>
        <email>christine.sumbi@csmns.org</email>
      </contact_backup>
      <investigator>
        <last_name>Jignesh Patel, MD</last_name>
        <role>Principal Investigator</role>
      </investigator>
      <investigator>
        <last_name>Michelle Kittleson, MD,PhD</last_name>
        <role>Sub-Investigator</role>
      </investigator>
    </location>
    <location>
      <facility>
        <name>Tufts Medical Center</name>
        <address>
          <city>Boston</city>
          <state>Massachusetts</state>
          <zip>02111</zip>
          <country>United States</country>
        </address>
      </facility>
      <contact>
        <last_name>Ayan Patel, MD</last_name>
        <phone>617-636-4184</phone>
        <email>ayan.patel@tuftsmedicine.org</email>
      </contact>
      <contact_backup>
        <last_name>James Kryzanski, MD</last_name>
        <phone>617-636-8585</phone>
        <email>james.kryzanski@tuftsmedicine.org</email>
      </contact_backup>
      <investigator>
        <last_name>Ayan Patel, MD</last_name>
        <role>Principal Investigator</role>
      </investigator>
      <investigator>
        <last_name>James Kryzanski, MD</last_name>
        <role>Sub-Investigator</role>
      </investigator>
    </location>
    <location>
      <facility>
        <name>Boston Medical Center</name>
        <address>
          <city>Boston</city>
          <state>Massachusetts</state>
          <zip>02359</zip>
          <country>United States</country>
        </address>
      </facility>
      <contact>
        <last_name>Frederick Ruberg, MD</last_name>
        <phone>617-638-8771</phone>
        <email>frederick.ruberg@bmc.org</email>
      </contact>
      <contact_backup>
        <last_name>Denise Fine</last_name>
        <phone>617-638-8716</phone>
        <email>denise.fine@bmc.org</email>
      </contact_backup>
      <investigator>
        <last_name>Frederick Ruberg, MD</last_name>
        <role>Principal Investigator</role>
      </investigator>
    </location>
    <location>
      <facility>
        <name>Mayo Clinic</name>
        <address>
          <city>Rochester</city>
          <state>Minnesota</state>
          <zip>55905</zip>
          <country>United States</country>
        </address>
      </facility>
      <contact>
        <last_name>Ellen McPhail, MD</last_name>
        <phone>507-538-1472</phone>
        <email>McPhail.ellen@mayo.edu</email>
      </contact>
      <contact_backup>
        <last_name>Research and Innovation Office (RIO)</last_name>
        <phone>507-284-9080</phone>
        <email>dlmprio@mayo.edu</email>
      </contact_backup>
      <investigator>
        <last_name>Ellen McPhail, MD</last_name>
        <role>Principal Investigator</role>
      </investigator>
    </location>
    <location>
      <facility>
        <name>Columbia University Irving Medical Center</name>
        <address>
          <city>New York</city>
          <state>New York</state>
          <zip>10032</zip>
          <country>United States</country>
        </address>
      </facility>
      <contact>
        <last_name>Jeffeny DeLosSantos, MHA</last_name>
        <phone>212-932-4537</phone>
        <email>jd3456@cumc.columbia.edu</email>
      </contact>
      <contact_backup>
        <last_name>Samantha L Guadalupe, MHA</last_name>
        <phone>212-932-4537</phone>
        <email>slg2172@cumc.columbia.edu</email>
      </contact_backup>
      <investigator>
        <last_name>Mathew S Maurer, MD</last_name>
        <role>Principal Investigator</role>
      </investigator>
    </location>
    <location>
      <facility>
        <name>Cleveland Clinic</name>
        <address>
          <city>Cleveland</city>
          <state>Ohio</state>
          <zip>44195</zip>
          <country>United States</country>
        </address>
      </facility>
      <contact>
        <last_name>Mazen Hanna, MD</last_name>
        <phone>216-444-3490</phone>
        <email>hannam@ccf.org</email>
      </contact>
      <contact_backup>
        <last_name>Lauren Ives, RN</last_name>
        <phone>216-316-3370</phone>
        <email>ivesl@ccf.org</email>
      </contact_backup>
      <investigator>
        <last_name>Mazen Hanna, MD</last_name>
        <role>Principal Investigator</role>
      </investigator>
    </location>
    <location_countries>
      <country>United States</country>
    </location_countries>
    <reference>
      <citation>Upadhya B, Pisani B, Kitzman DW. Evolution of a Geriatric Syndrome: Pathophysiology and Treatment of Heart Failure with Preserved Ejection Fraction. J Am Geriatr Soc. 2017 Nov;65(11):2431-2440. doi: 10.1111/jgs.15141.</citation>
      <PMID>29124734</PMID>
    </reference>
    <reference>
      <citation>Ruberg FL, Grogan M, Hanna M, Kelly JW, Maurer MS. Transthyretin Amyloid Cardiomyopathy: JACC State-of-the-Art Review. J Am Coll Cardiol. 2019 Jun 11;73(22):2872-2891. doi: 10.1016/j.jacc.2019.04.003.</citation>
      <PMID>31171094</PMID>
    </reference>
    <reference>
      <citation>Griffin JM, Rosenblum H, Maurer MS. Pathophysiology and Therapeutic Approaches to Cardiac Amyloidosis. Circ Res. 2021 May 14;128(10):1554-1575. doi: 10.1161/CIRCRESAHA.121.318187. Epub 2021 May 13.</citation>
      <PMID>33983835</PMID>
    </reference>
    <reference>
      <citation>AbouEzzeddine OF, Davies DR, Scott CG, Fayyaz AU, Askew JW, McKie PM, Noseworthy PA, Johnson GB, Dunlay SM, Borlaug BA, Chareonthaitawee P, Roger VL, Dispenzieri A, Grogan M, Redfield MM. Prevalence of Transthyretin Amyloid Cardiomyopathy in Heart Failure With Preserved Ejection Fraction. JAMA Cardiol. 2021 Nov 1;6(11):1267-1274. doi: 10.1001/jamacardio.2021.3070. Erratum In: JAMA Cardiol. 2021 Oct 6;:null.</citation>
      <PMID>34431962</PMID>
    </reference>
    <reference>
      <citation>Gonzalez-Lopez E, Gallego-Delgado M, Guzzo-Merello G, de Haro-Del Moral FJ, Cobo-Marcos M, Robles C, Bornstein B, Salas C, Lara-Pezzi E, Alonso-Pulpon L, Garcia-Pavia P. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. Eur Heart J. 2015 Oct 7;36(38):2585-94. doi: 10.1093/eurheartj/ehv338. Epub 2015 Jul 28.</citation>
      <PMID>26224076</PMID>
    </reference>
    <reference>
      <citation>Castano A, Narotsky DL, Hamid N, Khalique OK, Morgenstern R, DeLuca A, Rubin J, Chiuzan C, Nazif T, Vahl T, George I, Kodali S, Leon MB, Hahn R, Bokhari S, Maurer MS. Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement. Eur Heart J. 2017 Oct 7;38(38):2879-2887. doi: 10.1093/eurheartj/ehx350.</citation>
      <PMID>29019612</PMID>
    </reference>
    <reference>
      <citation>Maurer MS, Schwartz JH, Gundapaneni B, Elliott PM, Merlini G, Waddington-Cruz M, Kristen AV, Grogan M, Witteles R, Damy T, Drachman BM, Shah SJ, Hanna M, Judge DP, Barsdorf AI, Huber P, Patterson TA, Riley S, Schumacher J, Stewart M, Sultan MB, Rapezzi C; ATTR-ACT Study Investigators. Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy. N Engl J Med. 2018 Sep 13;379(11):1007-1016. doi: 10.1056/NEJMoa1805689. Epub 2018 Aug 27.</citation>
      <PMID>30145929</PMID>
    </reference>
    <reference>
      <citation>Griffin JM, Maurer MS. Transthyretin cardiac amyloidosis: A treatable form of heart failure with a preserved ejection fraction. Trends Cardiovasc Med. 2021 Jan;31(1):59-66. doi: 10.1016/j.tcm.2019.12.003. Epub 2019 Dec 17.</citation>
      <PMID>31889610</PMID>
    </reference>
    <reference>
      <citation>Adams D, Gonzalez-Duarte A, O'Riordan WD, Yang CC, Ueda M, Kristen AV, Tournev I, Schmidt HH, Coelho T, Berk JL, Lin KP, Vita G, Attarian S, Plante-Bordeneuve V, Mezei MM, Campistol JM, Buades J, Brannagan TH 3rd, Kim BJ, Oh J, Parman Y, Sekijima Y, Hawkins PN, Solomon SD, Polydefkis M, Dyck PJ, Gandhi PJ, Goyal S, Chen J, Strahs AL, Nochur SV, Sweetser MT, Garg PP, Vaishnaw AK, Gollob JA, Suhr OB. Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis. N Engl J Med. 2018 Jul 5;379(1):11-21. doi: 10.1056/NEJMoa1716153.</citation>
      <PMID>29972753</PMID>
    </reference>
    <reference>
      <citation>Benson MD, Waddington-Cruz M, Berk JL, Polydefkis M, Dyck PJ, Wang AK, Plante-Bordeneuve V, Barroso FA, Merlini G, Obici L, Scheinberg M, Brannagan TH 3rd, Litchy WJ, Whelan C, Drachman BM, Adams D, Heitner SB, Conceicao I, Schmidt HH, Vita G, Campistol JM, Gamez J, Gorevic PD, Gane E, Shah AM, Solomon SD, Monia BP, Hughes SG, Kwoh TJ, McEvoy BW, Jung SW, Baker BF, Ackermann EJ, Gertz MA, Coelho T. Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis. N Engl J Med. 2018 Jul 5;379(1):22-31. doi: 10.1056/NEJMoa1716793.</citation>
      <PMID>29972757</PMID>
    </reference>
    <reference>
      <citation>Gillmore JD, Gane E, Taubel J, Kao J, Fontana M, Maitland ML, Seitzer J, O'Connell D, Walsh KR, Wood K, Phillips J, Xu Y, Amaral A, Boyd AP, Cehelsky JE, McKee MD, Schiermeier A, Harari O, Murphy A, Kyratsous CA, Zambrowicz B, Soltys R, Gutstein DE, Leonard J, Sepp-Lorenzino L, Lebwohl D. CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis. N Engl J Med. 2021 Aug 5;385(6):493-502. doi: 10.1056/NEJMoa2107454. Epub 2021 Jun 26.</citation>
      <PMID>34215024</PMID>
    </reference>
    <reference>
      <citation>Maurer MS. Gene Editing - A Cure for Transthyretin Amyloidosis? N Engl J Med. 2021 Aug 5;385(6):558-559. doi: 10.1056/NEJMe2110557. No abstract available.</citation>
      <PMID>34347958</PMID>
    </reference>
    <reference>
      <citation>Maurer MS, Mann DL. The Tafamidis Drug Development Program: A Translational Triumph. JACC Basic Transl Sci. 2018 Dec 31;3(6):871-873. doi: 10.1016/j.jacbts.2018.10.001. eCollection 2018 Dec. No abstract available.</citation>
      <PMID>30623146</PMID>
    </reference>
    <reference>
      <citation>Nativi-Nicolau JN, Karam C, Khella S, Maurer MS. Screening for ATTR amyloidosis in the clinic: overlapping disorders, misdiagnosis, and multiorgan awareness. Heart Fail Rev. 2022 May;27(3):785-793. doi: 10.1007/s10741-021-10080-2. Epub 2021 Feb 20.</citation>
      <PMID>33609196</PMID>
    </reference>
    <reference>
      <citation>Donnelly JP, Hanna M, Sperry BW, Seitz WH Jr. Carpal Tunnel Syndrome: A Potential Early, Red-Flag Sign of Amyloidosis. J Hand Surg Am. 2019 Oct;44(10):868-876. doi: 10.1016/j.jhsa.2019.06.016. Epub 2019 Aug 7.</citation>
      <PMID>31400950</PMID>
    </reference>
    <reference>
      <citation>Sperry BW, Reyes BA, Ikram A, Donnelly JP, Phelan D, Jaber WA, Shapiro D, Evans PJ, Maschke S, Kilpatrick SE, Tan CD, Rodriguez ER, Monteiro C, Tang WHW, Kelly JW, Seitz WH Jr, Hanna M. Tenosynovial and Cardiac Amyloidosis in Patients Undergoing Carpal Tunnel Release. J Am Coll Cardiol. 2018 Oct 23;72(17):2040-2050. doi: 10.1016/j.jacc.2018.07.092.</citation>
      <PMID>30336828</PMID>
    </reference>
    <reference>
      <citation>Geller HI, Singh A, Alexander KM, Mirto TM, Falk RH. Association Between Ruptured Distal Biceps Tendon and Wild-Type Transthyretin Cardiac Amyloidosis. JAMA. 2017 Sep 12;318(10):962-963. doi: 10.1001/jama.2017.9236.</citation>
      <PMID>28898370</PMID>
    </reference>
    <reference>
      <citation>Rubin J, Alvarez J, Teruya S, Castano A, Lehman RA, Weidenbaum M, Geller JA, Helmke S, Maurer MS. Hip and knee arthroplasty are common among patients with transthyretin cardiac amyloidosis, occurring years before cardiac amyloid diagnosis: can we identify affected patients earlier? Amyloid. 2017 Dec;24(4):226-230. doi: 10.1080/13506129.2017.1375908. Epub 2017 Sep 14.</citation>
      <PMID>28906148</PMID>
    </reference>
    <reference>
      <citation>George KM, Dowd RS, Nail J, Yu A, Mastroianni M, Wang AY, Arkun K, Patel A, Kryzanski J, Comenzo R, Riesenburger RI. Wild-Type Transthyretin Amyloidosis Occurring in the Ligamentum Flavum of the Cervicothoracic Spine. World Neurosurg. 2020 Oct;142:e325-e330. doi: 10.1016/j.wneu.2020.06.228. Epub 2020 Jul 8.</citation>
      <PMID>32652280</PMID>
    </reference>
    <reference>
      <citation>George KM, Hernandez NS, Breton J, Cooper B, Dowd RS, Nail J, Yu A, Mastroianni M, Wang A, Godara A, Zhang D, Arkun K, Patel AR, Varga C, Soto O, Kryzanski J, Comenzo R, Riesenburger R. Lumbar ligamentum flavum burden: Evaluating the role of ATTRwt amyloid deposition in ligamentum flavum thickness at all lumbar levels. Clin Neurol Neurosurg. 2021 Jul;206:106708. doi: 10.1016/j.clineuro.2021.106708. Epub 2021 May 25.</citation>
      <PMID>34053807</PMID>
    </reference>
    <reference>
      <citation>Westermark P, Westermark GT, Suhr OB, Berg S. Transthyretin-derived amyloidosis: probably a common cause of lumbar spinal stenosis. Ups J Med Sci. 2014 Aug;119(3):223-8. doi: 10.3109/03009734.2014.895786. Epub 2014 Mar 12.</citation>
      <PMID>24620715</PMID>
    </reference>
    <reference>
      <citation>Yanagisawa A, Ueda M, Sueyoshi T, Okada T, Fujimoto T, Ogi Y, Kitagawa K, Tasaki M, Misumi Y, Oshima T, Jono H, Obayashi K, Hirakawa K, Uchida H, Westermark P, Ando Y, Mizuta H. Amyloid deposits derived from transthyretin in the ligamentum flavum as related to lumbar spinal canal stenosis. Mod Pathol. 2015 Feb;28(2):201-7. doi: 10.1038/modpathol.2014.102. Epub 2014 Sep 5.</citation>
      <PMID>25189643</PMID>
    </reference>
    <reference>
      <citation>Basdavanos A, Maurer MS, Ives L, Derwin K, Ricchetti ET, Seitz W, Hanna M. Prevalence of Orthopedic Manifestations in Patients With Cardiac Amyloidosis With a Focus on Shoulder Pathologies. Am J Cardiol. 2023 Mar 1;190:67-74. doi: 10.1016/j.amjcard.2022.11.014. Epub 2022 Dec 23.</citation>
      <PMID>36566619</PMID>
    </reference>
    <reference>
      <citation>Westin O, Fosbol EL, Maurer MS, Leicht BP, Hasbak P, Mylin AK, Rorvig S, Lindkaer TH, Johannesen HH, Gustafsson F. Screening for Cardiac Amyloidosis 5 to 15 Years After Surgery for Bilateral Carpal Tunnel Syndrome. J Am Coll Cardiol. 2022 Sep 6;80(10):967-977. doi: 10.1016/j.jacc.2022.06.026.</citation>
      <PMID>36049804</PMID>
    </reference>
    <reference>
      <citation>Bhuiyan T, Helmke S, Patel AR, Ruberg FL, Packman J, Cheung K, Grogan D, Maurer MS. Pressure-volume relationships in patients with transthyretin (ATTR) cardiac amyloidosis secondary to V122I mutations and wild-type transthyretin: Transthyretin Cardiac Amyloid Study (TRACS). Circ Heart Fail. 2011 Mar;4(2):121-8. doi: 10.1161/CIRCHEARTFAILURE.109.910455. Epub 2010 Dec 29.</citation>
      <PMID>21191093</PMID>
    </reference>
    <reference>
      <citation>Hilmy AM, el-Domiaty NA, Daabees AY, Abou Taleb EM. The use of the chelating agent EDTA in the treatment of acute cadmium toxicity, tissue distribution and some blood parameters in the Egyptian toad Bufo regularis. Comp Biochem Physiol C Comp Pharmacol Toxicol. 1986;85(1):67-74. doi: 10.1016/0742-8413(86)90053-8.</citation>
      <PMID>2877808</PMID>
    </reference>
    <reference>
      <citation>Saith SE, Maurer MS, Patel AR. Systemic Amyloidosis due to Monoclonal Immunoglobulins: Cardiac Involvement. Hematol Oncol Clin North Am. 2020 Dec;34(6):1055-1068. doi: 10.1016/j.hoc.2020.07.006. Epub 2020 Sep 14.</citation>
      <PMID>33099423</PMID>
    </reference>
    <reference>
      <citation>Hanna M, Damy T, Grogan M, Stewart M, Gundapaneni B, Patterson TA, Schwartz JH, Sultan MB, Maurer MS. Impact of Tafamidis on Health-Related Quality of Life in Patients With Transthyretin Amyloid Cardiomyopathy (from the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial). Am J Cardiol. 2021 Feb 15;141:98-105. doi: 10.1016/j.amjcard.2020.10.066. Epub 2020 Nov 19.</citation>
      <PMID>33220323</PMID>
    </reference>
    <reference>
      <citation>Hanna M, Damy T, Grogan M, Stewart M, Gundapaneni B, Sultan MB, Maurer MS. Tafamidis and quality of life in people with transthyretin amyloid cardiomyopathy in the study ATTR-ACT: A plain language summary. Future Cardiol. 2022 Mar;18(3):165-172. doi: 10.2217/fca-2021-0095. Epub 2021 Nov 15.</citation>
      <PMID>34779246</PMID>
    </reference>
    <reference>
      <citation>Hanna M, Ruberg FL, Maurer MS, Dispenzieri A, Dorbala S, Falk RH, Hoffman J, Jaber W, Soman P, Witteles RM, Grogan M. Cardiac Scintigraphy With Technetium-99m-Labeled Bone-Seeking Tracers for Suspected Amyloidosis: JACC Review Topic of the Week. J Am Coll Cardiol. 2020 Jun 9;75(22):2851-2862. doi: 10.1016/j.jacc.2020.04.022.</citation>
      <PMID>32498813</PMID>
    </reference>
    <reference>
      <citation>Hartnett J, Jaber W, Maurer M, Sperry B, Hanna M, Collier P, Patel DR, Wazni OM, Donnellan E. Electrophysiological Manifestations of Cardiac Amyloidosis: JACC: CardioOncology State-of-the-Art Review. JACC CardioOncol. 2021 Oct 19;3(4):506-515. doi: 10.1016/j.jaccao.2021.07.010. eCollection 2021 Oct.</citation>
      <PMID>34729522</PMID>
    </reference>
    <reference>
      <citation>Judge DP, Heitner SB, Falk RH, Maurer MS, Shah SJ, Witteles RM, Grogan M, Selby VN, Jacoby D, Hanna M, Nativi-Nicolau J, Patel J, Rao S, Sinha U, Turtle CW, Fox JC. Transthyretin Stabilization by AG10 in Symptomatic Transthyretin Amyloid Cardiomyopathy. J Am Coll Cardiol. 2019 Jul 23;74(3):285-295. doi: 10.1016/j.jacc.2019.03.012. Epub 2019 Mar 15.</citation>
      <PMID>30885685</PMID>
    </reference>
    <reference>
      <citation>Judge DP, Kristen AV, Grogan M, Maurer MS, Falk RH, Hanna M, Gillmore J, Garg P, Vaishnaw AK, Harrop J, Powell C, Karsten V, Zhang X, Sweetser MT, Vest J, Hawkins PN. Phase 3 Multicenter Study of Revusiran in Patients with Hereditary Transthyretin-Mediated (hATTR) Amyloidosis with Cardiomyopathy (ENDEAVOUR). Cardiovasc Drugs Ther. 2020 Jun;34(3):357-370. doi: 10.1007/s10557-019-06919-4. Erratum In: Cardiovasc Drugs Ther. 2020 Jun 16;:</citation>
      <PMID>32062791</PMID>
    </reference>
    <reference>
      <citation>Maurer MS, Hanna M, Grogan M, Dispenzieri A, Witteles R, Drachman B, Judge DP, Lenihan DJ, Gottlieb SS, Shah SJ, Steidley DE, Ventura H, Murali S, Silver MA, Jacoby D, Fedson S, Hummel SL, Kristen AV, Damy T, Plante-Bordeneuve V, Coelho T, Mundayat R, Suhr OB, Waddington Cruz M, Rapezzi C; THAOS Investigators. Genotype and Phenotype of Transthyretin Cardiac Amyloidosis: THAOS (Transthyretin Amyloid Outcome Survey). J Am Coll Cardiol. 2016 Jul 12;68(2):161-72. doi: 10.1016/j.jacc.2016.03.596.</citation>
      <PMID>27386769</PMID>
    </reference>
    <reference>
      <citation>Sueyoshi T, Ueda M, Jono H, Irie H, Sei A, Ide J, Ando Y, Mizuta H. Wild-type transthyretin-derived amyloidosis in various ligaments and tendons. Hum Pathol. 2011 Sep;42(9):1259-64. doi: 10.1016/j.humpath.2010.11.017. Epub 2011 Feb 21.</citation>
      <PMID>21334722</PMID>
    </reference>
    <reference>
      <citation>Garcia-Pavia P, Rapezzi C, Adler Y, Arad M, Basso C, Brucato A, Burazor I, Caforio ALP, Damy T, Eriksson U, Fontana M, Gillmore JD, Gonzalez-Lopez E, Grogan M, Heymans S, Imazio M, Kindermann I, Kristen AV, Maurer MS, Merlini G, Pantazis A, Pankuweit S, Rigopoulos AG, Linhart A. Diagnosis and treatment of cardiac amyloidosis. A position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur J Heart Fail. 2021 Apr;23(4):512-526. doi: 10.1002/ejhf.2140. Epub 2021 Apr 7.</citation>
      <PMID>33826207</PMID>
    </reference>
    <reference>
      <citation>Kittleson MM, Maurer MS, Ambardekar AV, Bullock-Palmer RP, Chang PP, Eisen HJ, Nair AP, Nativi-Nicolau J, Ruberg FL; American Heart Association Heart Failure and Transplantation Committee of the Council on Clinical Cardiology. Cardiac Amyloidosis: Evolving Diagnosis and Management: A Scientific Statement From the American Heart Association. Circulation. 2020 Jul 7;142(1):e7-e22. doi: 10.1161/CIR.0000000000000792. Epub 2020 Jun 1. Erratum In: Circulation. 2021 Jul 6;144(1):e10. Circulation. 2021 Jul 6;144(1):e11.</citation>
      <PMID>32476490</PMID>
    </reference>
    <reference>
      <citation>Rapezzi C, Aimo A, Serenelli M, Barison A, Vergaro G, Passino C, Panichella G, Sinagra G, Merlo M, Fontana M, Gillmore J, Quarta CC, Maurer MS, Kittleson MM, Garcia-Pavia P, Emdin M. Critical Comparison of Documents From Scientific Societies on Cardiac Amyloidosis: JACC State-of-the-Art Review. J Am Coll Cardiol. 2022 Apr 5;79(13):1288-1303. doi: 10.1016/j.jacc.2022.01.036.</citation>
      <PMID>35361352</PMID>
    </reference>
    <reference>
      <citation>Nativi-Nicolau J, Siu A, Dispenzieri A, Maurer MS, Rapezzi C, Kristen AV, Garcia-Pavia P, LoRusso S, Waddington-Cruz M, Lairez O, Witteles R, Chapman D, Amass L, Grogan M; THAOS Investigators. Temporal Trends of Wild-Type Transthyretin Amyloid Cardiomyopathy in the Transthyretin Amyloidosis Outcomes Survey. JACC CardioOncol. 2021 Oct 19;3(4):537-546. doi: 10.1016/j.jaccao.2021.08.009. eCollection 2021 Oct.</citation>
      <PMID>34729526</PMID>
    </reference>
    <reference>
      <citation>Maurer MS, Elliott P, Comenzo R, Semigran M, Rapezzi C. Addressing Common Questions Encountered in the Diagnosis and Management of Cardiac Amyloidosis. Circulation. 2017 Apr 4;135(14):1357-1377. doi: 10.1161/CIRCULATIONAHA.116.024438.</citation>
      <PMID>28373528</PMID>
    </reference>
    <reference>
      <citation>Lane T, Fontana M, Martinez-Naharro A, Quarta CC, Whelan CJ, Petrie A, Rowczenio DM, Gilbertson JA, Hutt DF, Rezk T, Strehina SG, Caringal-Galima J, Manwani R, Sharpley FA, Wechalekar AD, Lachmann HJ, Mahmood S, Sachchithanantham S, Drage EPS, Jenner HD, McDonald R, Bertolli O, Calleja A, Hawkins PN, Gillmore JD. Natural History, Quality of Life, and Outcome in Cardiac Transthyretin Amyloidosis. Circulation. 2019 Jul 2;140(1):16-26. doi: 10.1161/CIRCULATIONAHA.118.038169. Epub 2019 May 21. Erratum In: Circulation. 2019 Jul 30;140(5):e185.</citation>
      <PMID>31109193</PMID>
    </reference>
    <reference>
      <citation>Rubin J, Maurer MS. Cardiac Amyloidosis: Overlooked, Underappreciated, and Treatable. Annu Rev Med. 2020 Jan 27;71:203-219. doi: 10.1146/annurev-med-052918-020140.</citation>
      <PMID>31986086</PMID>
    </reference>
    <reference>
      <citation>Gillmore JD, Maurer MS, Falk RH, Merlini G, Damy T, Dispenzieri A, Wechalekar AD, Berk JL, Quarta CC, Grogan M, Lachmann HJ, Bokhari S, Castano A, Dorbala S, Johnson GB, Glaudemans AW, Rezk T, Fontana M, Palladini G, Milani P, Guidalotti PL, Flatman K, Lane T, Vonberg FW, Whelan CJ, Moon JC, Ruberg FL, Miller EJ, Hutt DF, Hazenberg BP, Rapezzi C, Hawkins PN. Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis. Circulation. 2016 Jun 14;133(24):2404-12. doi: 10.1161/CIRCULATIONAHA.116.021612. Epub 2016 Apr 22.</citation>
      <PMID>27143678</PMID>
    </reference>
    <reference>
      <citation>Vrana JA, Gamez JD, Madden BJ, Theis JD, Bergen HR 3rd, Dogan A. Classification of amyloidosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimens. Blood. 2009 Dec 3;114(24):4957-9. doi: 10.1182/blood-2009-07-230722. Epub 2009 Oct 1.</citation>
      <PMID>19797517</PMID>
    </reference>
    <reference>
      <citation>Campanella G, Hanna MG, Geneslaw L, Miraflor A, Werneck Krauss Silva V, Busam KJ, Brogi E, Reuter VE, Klimstra DS, Fuchs TJ. Clinical-grade computational pathology using weakly supervised deep learning on whole slide images. Nat Med. 2019 Aug;25(8):1301-1309. doi: 10.1038/s41591-019-0508-1. Epub 2019 Jul 15.</citation>
      <PMID>31308507</PMID>
    </reference>
    <reference>
      <citation>Miller AB, Januzzi JL, O'Neill BJ, Gundapaneni B, Patterson TA, Sultan MB, Lopez-Sendon J. Causes of Cardiovascular Hospitalization and Death in Patients With Transthyretin Amyloid Cardiomyopathy (from the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial [ATTR-ACT]). Am J Cardiol. 2021 Jun 1;148:146-150. doi: 10.1016/j.amjcard.2021.02.035. Epub 2021 Mar 3.</citation>
      <PMID>33667442</PMID>
    </reference>
    <reference>
      <citation>Kubo SH, Schulman S, Starling RC, Jessup M, Wentworth D, Burkhoff D. Development and validation of a patient questionnaire to determine New York Heart Association classification. J Card Fail. 2004 Jun;10(3):228-35. doi: 10.1016/j.cardfail.2003.10.005.</citation>
      <PMID>15190533</PMID>
    </reference>
    <reference>
      <citation>ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med. 2002 Jul 1;166(1):111-7. doi: 10.1164/ajrccm.166.1.at1102. No abstract available. Erratum In: Am J Respir Crit Care Med. 2016 May 15;193(10):1185.</citation>
      <PMID>12091180</PMID>
    </reference>
    <reference>
      <citation>Guralnik JM, Simonsick EM, Ferrucci L, Glynn RJ, Berkman LF, Blazer DG, Scherr PA, Wallace RB. A short physical performance battery assessing lower extremity function: association with self-reported disability and prediction of mortality and nursing home admission. J Gerontol. 1994 Mar;49(2):M85-94. doi: 10.1093/geronj/49.2.m85.</citation>
      <PMID>8126356</PMID>
    </reference>
    <reference>
      <citation>Carroll JD, Gaasch WH, McAdam KP. Amyloid cardiomyopathy: characterization by a distinctive voltage/mass relation. Am J Cardiol. 1982 Jan;49(1):9-13. doi: 10.1016/0002-9149(82)90270-3.</citation>
      <PMID>6459025</PMID>
    </reference>
    <reference>
      <citation>Amundsen BH, Helle-Valle T, Edvardsen T, Torp H, Crosby J, Lyseggen E, Stoylen A, Ihlen H, Lima JA, Smiseth OA, Slordahl SA. Noninvasive myocardial strain measurement by speckle tracking echocardiography: validation against sonomicrometry and tagged magnetic resonance imaging. J Am Coll Cardiol. 2006 Feb 21;47(4):789-93. doi: 10.1016/j.jacc.2005.10.040. Epub 2006 Jan 26.</citation>
      <PMID>16487846</PMID>
    </reference>
    <reference>
      <citation>Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, Flachskampf FA, Foster E, Goldstein SA, Kuznetsova T, Lancellotti P, Muraru D, Picard MH, Rietzschel ER, Rudski L, Spencer KT, Tsang W, Voigt JU. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging. 2015 Mar;16(3):233-70. doi: 10.1093/ehjci/jev014. Erratum In: Eur Heart J Cardiovasc Imaging. 2016 Apr;17(4):412. Eur Heart J Cardiovasc Imaging. 2016 Sep;17 (9):969.</citation>
      <PMID>25712077</PMID>
    </reference>
    <reference>
      <citation>Devereux RB, Alonso DR, Lutas EM, Gottlieb GJ, Campo E, Sachs I, Reichek N. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol. 1986 Feb 15;57(6):450-8. doi: 10.1016/0002-9149(86)90771-x.</citation>
      <PMID>2936235</PMID>
    </reference>
    <reference>
      <citation>Mor-Avi V, Sugeng L, Weinert L, MacEneaney P, Caiani EG, Koch R, Salgo IS, Lang RM. Fast measurement of left ventricular mass with real-time three-dimensional echocardiography: comparison with magnetic resonance imaging. Circulation. 2004 Sep 28;110(13):1814-8. doi: 10.1161/01.CIR.0000142670.65971.5F. Epub 2004 Sep 20.</citation>
      <PMID>15381653</PMID>
    </reference>
    <reference>
      <citation>Takeuchi M, Nishikage T, Mor-Avi V, Sugeng L, Weinert L, Nakai H, Salgo IS, Gerard O, Lang RM. Measurement of left ventricular mass by real-time three-dimensional echocardiography: validation against magnetic resonance and comparison with two-dimensional and m-mode measurements. J Am Soc Echocardiogr. 2008 Sep;21(9):1001-5. doi: 10.1016/j.echo.2008.07.008.</citation>
      <PMID>18765176</PMID>
    </reference>
    <reference>
      <citation>Tendler A, Helmke S, Teruya S, Alvarez J, Maurer MS. The myocardial contraction fraction is superior to ejection fraction in predicting survival in patients with AL cardiac amyloidosis. Amyloid. 2015 Mar;22(1):61-6. doi: 10.3109/13506129.2014.994202. Epub 2014 Dec 16.</citation>
      <PMID>25510353</PMID>
    </reference>
    <reference>
      <citation>Bokhari S, Castano A, Pozniakoff T, Deslisle S, Latif F, Maurer MS. (99m)Tc-pyrophosphate scintigraphy for differentiating light-chain cardiac amyloidosis from the transthyretin-related familial and senile cardiac amyloidoses. Circ Cardiovasc Imaging. 2013 Mar 1;6(2):195-201. doi: 10.1161/CIRCIMAGING.112.000132. Epub 2013 Feb 11.</citation>
      <PMID>23400849</PMID>
    </reference>
    <reference>
      <citation>Cheng RK, Levy WC, Vasbinder A, Teruya S, De Los Santos J, Leedy D, Maurer MS. Diuretic Dose and NYHA Functional Class Are Independent Predictors of Mortality in Patients With Transthyretin Cardiac Amyloidosis. JACC CardioOncol. 2020 Sep;2(3):414-424. doi: 10.1016/j.jaccao.2020.06.007. Epub 2020 Sep 15.</citation>
      <PMID>33073249</PMID>
    </reference>
    <reference>
      <citation>Lee JY, Moon SH, Suh BK, Yang MH, Park MS. Outcome and Complications in Surgical Treatment of Lumbar Stenosis or Spondylolisthesis in Geriatric Patients. Yonsei Med J. 2015 Sep;56(5):1199-205. doi: 10.3349/ymj.2015.56.5.1199.</citation>
      <PMID>26256960</PMID>
    </reference>
    <reference>
      <citation>Kazi DS, Bellows BK, Baron SJ, Shen C, Cohen DJ, Spertus JA, Yeh RW, Arnold SV, Sperry BW, Maurer MS, Shah SJ. Cost-Effectiveness of Tafamidis Therapy for Transthyretin Amyloid Cardiomyopathy. Circulation. 2020 Apr 14;141(15):1214-1224. doi: 10.1161/CIRCULATIONAHA.119.045093. Epub 2020 Feb 12.</citation>
      <PMID>32078382</PMID>
    </reference>
    <reference>
      <citation>Ruiz-Negron N, Nativi-Nicolau J, Maurer MS, Moran AE, Kovacsovics T, Bellows BK. Cost-effectiveness of technetium pyrophosphate scintigraphy versus heart biopsy for the diagnosis of transthyretin amyloidosis. Amyloid. 2019;26(sup1):71-72. doi: 10.1080/13506129.2019.1583192. No abstract available.</citation>
      <PMID>31343305</PMID>
    </reference>
    <reference>
      <citation>Weintraub WS, Bhatt DL, Zhang Z, Dolman S, Boden WE, Bress AP, King JB, Bellows BK, Tajeu GS, Derington CG, Johnson J, Andrade K, Steg PG, Miller M, Brinton EA, Jacobson TA, Tardif JC, Ballantyne CM, Kolm P. Cost-effectiveness of Icosapent Ethyl for High-risk Patients With Hypertriglyceridemia Despite Statin Treatment. JAMA Netw Open. 2022 Feb 1;5(2):e2148172. doi: 10.1001/jamanetworkopen.2021.48172.</citation>
      <PMID>35157055</PMID>
    </reference>
    <reference>
      <citation>Zhang Z, Kolm P, Grau-Sepulveda MV, Ponirakis A, O'Brien SM, Klein LW, Shaw RE, McKay C, Shahian DM, Grover FL, Mayer JE, Garratt KN, Hlatky M, Edwards FH, Weintraub WS. Cost-effectiveness of revascularization strategies: the ASCERT study. J Am Coll Cardiol. 2015 Jan 6;65(1):1-11. doi: 10.1016/j.jacc.2014.09.078.</citation>
      <PMID>25572503</PMID>
    </reference>
    <reference>
      <citation>Zhang Z, Kolm P, Boden WE, Hartigan PM, Maron DJ, Spertus JA, O'Rourke RA, Shaw LJ, Sedlis SP, Mancini GB, Berman DS, Dada M, Teo KK, Weintraub WS. The cost-effectiveness of percutaneous coronary intervention as a function of angina severity in patients with stable angina. Circ Cardiovasc Qual Outcomes. 2011 Mar;4(2):172-82. doi: 10.1161/CIRCOUTCOMES.110.940502. Epub 2011 Feb 8.</citation>
      <PMID>21304091</PMID>
    </reference>
    <verification_date>September 2023</verification_date>
    <study_first_submitted>August 17, 2023</study_first_submitted>
    <study_first_submitted_qc>September 5, 2023</study_first_submitted_qc>
    <study_first_posted type="Actual">September 13, 2023</study_first_posted>
    <last_update_submitted>September 12, 2023</last_update_submitted>
    <last_update_submitted_qc>September 12, 2023</last_update_submitted_qc>
    <last_update_posted type="Actual">September 14, 2023</last_update_posted>
    <responsible_party>
      <responsible_party_type>Principal Investigator</responsible_party_type>
      <investigator_affiliation>Columbia University</investigator_affiliation>
      <investigator_full_name>Mathew S. Maurer, MD</investigator_full_name>
      <investigator_title>Arnold and Arlene Goldstein Professor of Cardiology (in Medicine, Dept of Medicine Cardiology)</investigator_title>
    </responsible_party>
    <condition_browse>
      <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
      <mesh_term>Spinal Stenosis</mesh_term>
      <mesh_term>Cardiomyopathies</mesh_term>
      <mesh_term>Cardiomyopathy, Hypertrophic</mesh_term>
      <mesh_term>Amyloidosis</mesh_term>
      <mesh_term>Constriction, Pathologic</mesh_term>
    </condition_browse>
    <patient_data>
      <sharing_ipd>Undecided</sharing_ipd>
    </patient_data>
    <!-- Results have not yet been posted for this study                                          -->
  </clinical_study>
  
  
text: download date: ClinicalTrials.gov processed this data on September 20, 2023
  link text: Link to the current ClinicalTrials.gov record.
  url: https://clinicaltrials.gov/ct2/show/NCT06034405
  org study id: AAAU4704
  nct id: NCT06034405
  lead sponsor: 
  collaborator: 
  has dmc: Yes
  is fda regulated drug: No
  is fda regulated device: No
  Primary objective:
  
        To identify older adults with transthyretin cardiac amyloidosis (ATTR-CA) early in the course
        of the illness, at a time when disease modifying therapies are most effective.
  
        The specific aims of this epidemiologic investigation include:
  
          1. To identify subjects with previous lumbar spinal stenosis (LSS) Surgery who have
             evidence of transthyretin (TTR) amyloid deposits in spinal specimens and could be at
             risk for ATTR cardiac amyloidosis.
  
          2. To evaluate for ATTR-CA among those with localized TTR in the spinal tissue.
  
        The study will also explore the following:
  
          1. The prevalence of amyloid in lumbar spinal stenosis specimens by Congo Red staining.
  
          2. The prevalence of TTR deposits among subjects with amyloid as determined by mass
             spectrometry.
  
          3. Evaluation of a novel artificial intelligence technique for that can identify amyloid
             histologically with standard H&E staining.
  
          4. Difference in ATTR-CA prevalence between subjects with TTR and indeterminate amyloid
             deposits in subject's spine by myocardial uptake of technetium pyrophosphate scan
             (Tc99-PYP).
  This is a multicenter, prospective cohort study aimed at facilitating identification of
        individuals with ATTR-CA. Investigators will identify subjects with previous LSS surgery who
        have evidence of TTR amyloid deposits in spinal specimens. Subjects with localized TTR in
        spinal tissue will be invited to an on-site visit and be evaluated for the presence of
        clinical manifestations of ATTR cardiac amyloidosis (ATTR-CA).
  
        Subjects will undergo nuclear scintigraphy, TTR genetic test, a clinical evaluation,
        electrocardiogram, and echocardiogram. Quality of life questionnaires will also be
        administered. Subjects who have myocardial retention of the imaging radiotracer with a
        Perugini score equal to 2 (uptake equal to bone) or 3 (uptake greater than bone) and
        confirmation by SPECT or SPECT/CT that the uptake is myocardial in nature and have no
        evidence of monoclonal proteins will be diagnosed with ATTR-CA.
  
        This study is to be conducted at five study sites: Boston Medical Center, Cedars Sinai
        Medical Center, Cleveland Clinic, Columbia University Irving Medical Center, and Tufts
        University Medical Center. The Mayo Clinic will serve a Pathology research core to analyze
        spine specimens.
  
        Most of the subjects are expected to complete all the study procedures and questionnaires on
        a single day.
  
        Up to 1663 patients will be consented in this study to have spinal specimens examined for the
        presence of amyloid by Congo Red at the Mayo Clinic core lab. From the pool of subjects with
        amyloid detected (which anticipate will be 33% or at least 544), the investigators expect to
        recruit 163 participants to undergo cardiac phenotyping (Tc99m and cardiac evaluation). Among
        the 163 participants who undergo cardiac phenotyping, 98 will have TTR as the precursor
        protein identified by mass spectrometry and 65 will have an indeterminant precursor protein
        by mass spectrometry.
  observational model: Cohort
  time perspective: Prospective
  measure: Percent of subjects with previous LSS surgery who have evidence of TTR amyloid deposits in their spinal specimen and could be at risk for ATTR cardiac amyloidosis
  time frame: up to 3 years
  description: To identify who can be at risk for ATTR Cardiac Amyloidosis. The investigator is going to collect spinal ligamentum flavum specimens and stain with congo red and those who result positive for ATTR amyloid in their spinal specimen will be counted
  measure: Percent of subjects with ATTR-CA among those with localized TTR in their spinal tissue
  time frame: up to 6 years
  description: To evaluate number of subjects with ATTR-CA among those with localized TTR in their spinal tissue. The investigator is going to perform standard of care (SOC) cardiac amyloidosis work up including PYP scan to confirm cardiac phenotype
  arm group label: ATTR Negative
  description: Participants who have undergone previous lumbar spinal, and/or carpel tunnel surgery will provide medical record data and spinal specimen for analysis of presence of ATTR amyloid.
  arm group label: ATTR Positive
  description: Participants who have undergone previous lumbar spinal, and/or carpel tunnel surgery will provide medical record data, spinal specimen, prospective data from cardiac workup with confirmed ATTR amyloid in spinal specimen then undergo cardiac workup for cardiac phenotyping/genotyping.
  intervention type: Diagnostic Test
  intervention name: Tc99-PYP or Tc99-HDMP Scan
  description: Difference in ATTR-CA prevalence between subjects with TTR and indeterminate amyloid deposits in their spine by myocardial uptake of Tc99-PYP.
  arm group label: ATTR Positive
  Blood will be drawn and analyzed for standard chemistry (Chem-7), liver function tests,
        NT-proBNP, troponin I and T, and TTR gene sequencing (see below). For subjects with ATTR-CA
        by positive uptake of 99mTc-PYP, further testing of prealbumin and monoclonal proteins (serum
        free light chains and immunofixation in serum and urine) will be performed. Additional
        aliquots will be stored at -80° for future analysis.
  study pop: 
  sampling method: Probability Sample
  criteria: 
  gender: All
  minimum age: 60 Years
  maximum age: N/A
  healthy volunteers: Accepts Healthy Volunteers
  last name: Mathew S Maurer, MD
  role: Principal Investigator
  affiliation: Columbia University
  last name: Mathew S Maurer, MD
  phone: 212-932-4537
  email: msm10@cumc.columbia.edu
  last name: Samantha L Guadalupe, MHA
  phone: 212-932-4537
  email: slg2172@cumc.columbia.edu
  facility: 
  contact: 
  contact backup: 
  investigator: 
  investigator: 
  facility: 
  contact: 
  contact backup: 
  investigator: 
  investigator: 
  facility: 
  contact: 
  contact backup: 
  investigator: 
  facility: 
  contact: 
  contact backup: 
  investigator: 
  facility: 
  contact: 
  contact backup: 
  investigator: 
  facility: 
  contact: 
  contact backup: 
  investigator: 
  country: United States
  citation: Upadhya B, Pisani B, Kitzman DW. Evolution of a Geriatric Syndrome: Pathophysiology and Treatment of Heart Failure with Preserved Ejection Fraction. J Am Geriatr Soc. 2017 Nov;65(11):2431-2440. doi: 10.1111/jgs.15141.
  PMID: 29124734
  citation: Ruberg FL, Grogan M, Hanna M, Kelly JW, Maurer MS. Transthyretin Amyloid Cardiomyopathy: JACC State-of-the-Art Review. J Am Coll Cardiol. 2019 Jun 11;73(22):2872-2891. doi: 10.1016/j.jacc.2019.04.003.
  PMID: 31171094
  citation: Griffin JM, Rosenblum H, Maurer MS. Pathophysiology and Therapeutic Approaches to Cardiac Amyloidosis. Circ Res. 2021 May 14;128(10):1554-1575. doi: 10.1161/CIRCRESAHA.121.318187. Epub 2021 May 13.
  PMID: 33983835
  citation: AbouEzzeddine OF, Davies DR, Scott CG, Fayyaz AU, Askew JW, McKie PM, Noseworthy PA, Johnson GB, Dunlay SM, Borlaug BA, Chareonthaitawee P, Roger VL, Dispenzieri A, Grogan M, Redfield MM. Prevalence of Transthyretin Amyloid Cardiomyopathy in Heart Failure With Preserved Ejection Fraction. JAMA Cardiol. 2021 Nov 1;6(11):1267-1274. doi: 10.1001/jamacardio.2021.3070. Erratum In: JAMA Cardiol. 2021 Oct 6;:null.
  PMID: 34431962
  citation: Gonzalez-Lopez E, Gallego-Delgado M, Guzzo-Merello G, de Haro-Del Moral FJ, Cobo-Marcos M, Robles C, Bornstein B, Salas C, Lara-Pezzi E, Alonso-Pulpon L, Garcia-Pavia P. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. Eur Heart J. 2015 Oct 7;36(38):2585-94. doi: 10.1093/eurheartj/ehv338. Epub 2015 Jul 28.
  PMID: 26224076
  citation: Castano A, Narotsky DL, Hamid N, Khalique OK, Morgenstern R, DeLuca A, Rubin J, Chiuzan C, Nazif T, Vahl T, George I, Kodali S, Leon MB, Hahn R, Bokhari S, Maurer MS. Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement. Eur Heart J. 2017 Oct 7;38(38):2879-2887. doi: 10.1093/eurheartj/ehx350.
  PMID: 29019612
  citation: Maurer MS, Schwartz JH, Gundapaneni B, Elliott PM, Merlini G, Waddington-Cruz M, Kristen AV, Grogan M, Witteles R, Damy T, Drachman BM, Shah SJ, Hanna M, Judge DP, Barsdorf AI, Huber P, Patterson TA, Riley S, Schumacher J, Stewart M, Sultan MB, Rapezzi C; ATTR-ACT Study Investigators. Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy. N Engl J Med. 2018 Sep 13;379(11):1007-1016. doi: 10.1056/NEJMoa1805689. Epub 2018 Aug 27.
  PMID: 30145929
  citation: Griffin JM, Maurer MS. Transthyretin cardiac amyloidosis: A treatable form of heart failure with a preserved ejection fraction. Trends Cardiovasc Med. 2021 Jan;31(1):59-66. doi: 10.1016/j.tcm.2019.12.003. Epub 2019 Dec 17.
  PMID: 31889610
  citation: Adams D, Gonzalez-Duarte A, O'Riordan WD, Yang CC, Ueda M, Kristen AV, Tournev I, Schmidt HH, Coelho T, Berk JL, Lin KP, Vita G, Attarian S, Plante-Bordeneuve V, Mezei MM, Campistol JM, Buades J, Brannagan TH 3rd, Kim BJ, Oh J, Parman Y, Sekijima Y, Hawkins PN, Solomon SD, Polydefkis M, Dyck PJ, Gandhi PJ, Goyal S, Chen J, Strahs AL, Nochur SV, Sweetser MT, Garg PP, Vaishnaw AK, Gollob JA, Suhr OB. Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis. N Engl J Med. 2018 Jul 5;379(1):11-21. doi: 10.1056/NEJMoa1716153.
  PMID: 29972753
  citation: Benson MD, Waddington-Cruz M, Berk JL, Polydefkis M, Dyck PJ, Wang AK, Plante-Bordeneuve V, Barroso FA, Merlini G, Obici L, Scheinberg M, Brannagan TH 3rd, Litchy WJ, Whelan C, Drachman BM, Adams D, Heitner SB, Conceicao I, Schmidt HH, Vita G, Campistol JM, Gamez J, Gorevic PD, Gane E, Shah AM, Solomon SD, Monia BP, Hughes SG, Kwoh TJ, McEvoy BW, Jung SW, Baker BF, Ackermann EJ, Gertz MA, Coelho T. Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis. N Engl J Med. 2018 Jul 5;379(1):22-31. doi: 10.1056/NEJMoa1716793.
  PMID: 29972757
  citation: Gillmore JD, Gane E, Taubel J, Kao J, Fontana M, Maitland ML, Seitzer J, O'Connell D, Walsh KR, Wood K, Phillips J, Xu Y, Amaral A, Boyd AP, Cehelsky JE, McKee MD, Schiermeier A, Harari O, Murphy A, Kyratsous CA, Zambrowicz B, Soltys R, Gutstein DE, Leonard J, Sepp-Lorenzino L, Lebwohl D. CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis. N Engl J Med. 2021 Aug 5;385(6):493-502. doi: 10.1056/NEJMoa2107454. Epub 2021 Jun 26.
  PMID: 34215024
  citation: Maurer MS. Gene Editing - A Cure for Transthyretin Amyloidosis? N Engl J Med. 2021 Aug 5;385(6):558-559. doi: 10.1056/NEJMe2110557. No abstract available.
  PMID: 34347958
  citation: Maurer MS, Mann DL. The Tafamidis Drug Development Program: A Translational Triumph. JACC Basic Transl Sci. 2018 Dec 31;3(6):871-873. doi: 10.1016/j.jacbts.2018.10.001. eCollection 2018 Dec. No abstract available.
  PMID: 30623146
  citation: Nativi-Nicolau JN, Karam C, Khella S, Maurer MS. Screening for ATTR amyloidosis in the clinic: overlapping disorders, misdiagnosis, and multiorgan awareness. Heart Fail Rev. 2022 May;27(3):785-793. doi: 10.1007/s10741-021-10080-2. Epub 2021 Feb 20.
  PMID: 33609196
  citation: Donnelly JP, Hanna M, Sperry BW, Seitz WH Jr. Carpal Tunnel Syndrome: A Potential Early, Red-Flag Sign of Amyloidosis. J Hand Surg Am. 2019 Oct;44(10):868-876. doi: 10.1016/j.jhsa.2019.06.016. Epub 2019 Aug 7.
  PMID: 31400950
  citation: Sperry BW, Reyes BA, Ikram A, Donnelly JP, Phelan D, Jaber WA, Shapiro D, Evans PJ, Maschke S, Kilpatrick SE, Tan CD, Rodriguez ER, Monteiro C, Tang WHW, Kelly JW, Seitz WH Jr, Hanna M. Tenosynovial and Cardiac Amyloidosis in Patients Undergoing Carpal Tunnel Release. J Am Coll Cardiol. 2018 Oct 23;72(17):2040-2050. doi: 10.1016/j.jacc.2018.07.092.
  PMID: 30336828
  citation: Geller HI, Singh A, Alexander KM, Mirto TM, Falk RH. Association Between Ruptured Distal Biceps Tendon and Wild-Type Transthyretin Cardiac Amyloidosis. JAMA. 2017 Sep 12;318(10):962-963. doi: 10.1001/jama.2017.9236.
  PMID: 28898370
  citation: Rubin J, Alvarez J, Teruya S, Castano A, Lehman RA, Weidenbaum M, Geller JA, Helmke S, Maurer MS. Hip and knee arthroplasty are common among patients with transthyretin cardiac amyloidosis, occurring years before cardiac amyloid diagnosis: can we identify affected patients earlier? Amyloid. 2017 Dec;24(4):226-230. doi: 10.1080/13506129.2017.1375908. Epub 2017 Sep 14.
  PMID: 28906148
  citation: George KM, Dowd RS, Nail J, Yu A, Mastroianni M, Wang AY, Arkun K, Patel A, Kryzanski J, Comenzo R, Riesenburger RI. Wild-Type Transthyretin Amyloidosis Occurring in the Ligamentum Flavum of the Cervicothoracic Spine. World Neurosurg. 2020 Oct;142:e325-e330. doi: 10.1016/j.wneu.2020.06.228. Epub 2020 Jul 8.
  PMID: 32652280
  citation: George KM, Hernandez NS, Breton J, Cooper B, Dowd RS, Nail J, Yu A, Mastroianni M, Wang A, Godara A, Zhang D, Arkun K, Patel AR, Varga C, Soto O, Kryzanski J, Comenzo R, Riesenburger R. Lumbar ligamentum flavum burden: Evaluating the role of ATTRwt amyloid deposition in ligamentum flavum thickness at all lumbar levels. Clin Neurol Neurosurg. 2021 Jul;206:106708. doi: 10.1016/j.clineuro.2021.106708. Epub 2021 May 25.
  PMID: 34053807
  citation: Westermark P, Westermark GT, Suhr OB, Berg S. Transthyretin-derived amyloidosis: probably a common cause of lumbar spinal stenosis. Ups J Med Sci. 2014 Aug;119(3):223-8. doi: 10.3109/03009734.2014.895786. Epub 2014 Mar 12.
  PMID: 24620715
  citation: Yanagisawa A, Ueda M, Sueyoshi T, Okada T, Fujimoto T, Ogi Y, Kitagawa K, Tasaki M, Misumi Y, Oshima T, Jono H, Obayashi K, Hirakawa K, Uchida H, Westermark P, Ando Y, Mizuta H. Amyloid deposits derived from transthyretin in the ligamentum flavum as related to lumbar spinal canal stenosis. Mod Pathol. 2015 Feb;28(2):201-7. doi: 10.1038/modpathol.2014.102. Epub 2014 Sep 5.
  PMID: 25189643
  citation: Basdavanos A, Maurer MS, Ives L, Derwin K, Ricchetti ET, Seitz W, Hanna M. Prevalence of Orthopedic Manifestations in Patients With Cardiac Amyloidosis With a Focus on Shoulder Pathologies. Am J Cardiol. 2023 Mar 1;190:67-74. doi: 10.1016/j.amjcard.2022.11.014. Epub 2022 Dec 23.
  PMID: 36566619
  citation: Westin O, Fosbol EL, Maurer MS, Leicht BP, Hasbak P, Mylin AK, Rorvig S, Lindkaer TH, Johannesen HH, Gustafsson F. Screening for Cardiac Amyloidosis 5 to 15 Years After Surgery for Bilateral Carpal Tunnel Syndrome. J Am Coll Cardiol. 2022 Sep 6;80(10):967-977. doi: 10.1016/j.jacc.2022.06.026.
  PMID: 36049804
  citation: Bhuiyan T, Helmke S, Patel AR, Ruberg FL, Packman J, Cheung K, Grogan D, Maurer MS. Pressure-volume relationships in patients with transthyretin (ATTR) cardiac amyloidosis secondary to V122I mutations and wild-type transthyretin: Transthyretin Cardiac Amyloid Study (TRACS). Circ Heart Fail. 2011 Mar;4(2):121-8. doi: 10.1161/CIRCHEARTFAILURE.109.910455. Epub 2010 Dec 29.
  PMID: 21191093
  citation: Hilmy AM, el-Domiaty NA, Daabees AY, Abou Taleb EM. The use of the chelating agent EDTA in the treatment of acute cadmium toxicity, tissue distribution and some blood parameters in the Egyptian toad Bufo regularis. Comp Biochem Physiol C Comp Pharmacol Toxicol. 1986;85(1):67-74. doi: 10.1016/0742-8413(86)90053-8.
  PMID: 2877808
  citation: Saith SE, Maurer MS, Patel AR. Systemic Amyloidosis due to Monoclonal Immunoglobulins: Cardiac Involvement. Hematol Oncol Clin North Am. 2020 Dec;34(6):1055-1068. doi: 10.1016/j.hoc.2020.07.006. Epub 2020 Sep 14.
  PMID: 33099423
  citation: Hanna M, Damy T, Grogan M, Stewart M, Gundapaneni B, Patterson TA, Schwartz JH, Sultan MB, Maurer MS. Impact of Tafamidis on Health-Related Quality of Life in Patients With Transthyretin Amyloid Cardiomyopathy (from the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial). Am J Cardiol. 2021 Feb 15;141:98-105. doi: 10.1016/j.amjcard.2020.10.066. Epub 2020 Nov 19.
  PMID: 33220323
  citation: Hanna M, Damy T, Grogan M, Stewart M, Gundapaneni B, Sultan MB, Maurer MS. Tafamidis and quality of life in people with transthyretin amyloid cardiomyopathy in the study ATTR-ACT: A plain language summary. Future Cardiol. 2022 Mar;18(3):165-172. doi: 10.2217/fca-2021-0095. Epub 2021 Nov 15.
  PMID: 34779246
  citation: Hanna M, Ruberg FL, Maurer MS, Dispenzieri A, Dorbala S, Falk RH, Hoffman J, Jaber W, Soman P, Witteles RM, Grogan M. Cardiac Scintigraphy With Technetium-99m-Labeled Bone-Seeking Tracers for Suspected Amyloidosis: JACC Review Topic of the Week. J Am Coll Cardiol. 2020 Jun 9;75(22):2851-2862. doi: 10.1016/j.jacc.2020.04.022.
  PMID: 32498813
  citation: Hartnett J, Jaber W, Maurer M, Sperry B, Hanna M, Collier P, Patel DR, Wazni OM, Donnellan E. Electrophysiological Manifestations of Cardiac Amyloidosis: JACC: CardioOncology State-of-the-Art Review. JACC CardioOncol. 2021 Oct 19;3(4):506-515. doi: 10.1016/j.jaccao.2021.07.010. eCollection 2021 Oct.
  PMID: 34729522
  citation: Judge DP, Heitner SB, Falk RH, Maurer MS, Shah SJ, Witteles RM, Grogan M, Selby VN, Jacoby D, Hanna M, Nativi-Nicolau J, Patel J, Rao S, Sinha U, Turtle CW, Fox JC. Transthyretin Stabilization by AG10 in Symptomatic Transthyretin Amyloid Cardiomyopathy. J Am Coll Cardiol. 2019 Jul 23;74(3):285-295. doi: 10.1016/j.jacc.2019.03.012. Epub 2019 Mar 15.
  PMID: 30885685
  citation: Judge DP, Kristen AV, Grogan M, Maurer MS, Falk RH, Hanna M, Gillmore J, Garg P, Vaishnaw AK, Harrop J, Powell C, Karsten V, Zhang X, Sweetser MT, Vest J, Hawkins PN. Phase 3 Multicenter Study of Revusiran in Patients with Hereditary Transthyretin-Mediated (hATTR) Amyloidosis with Cardiomyopathy (ENDEAVOUR). Cardiovasc Drugs Ther. 2020 Jun;34(3):357-370. doi: 10.1007/s10557-019-06919-4. Erratum In: Cardiovasc Drugs Ther. 2020 Jun 16;:
  PMID: 32062791
  citation: Maurer MS, Hanna M, Grogan M, Dispenzieri A, Witteles R, Drachman B, Judge DP, Lenihan DJ, Gottlieb SS, Shah SJ, Steidley DE, Ventura H, Murali S, Silver MA, Jacoby D, Fedson S, Hummel SL, Kristen AV, Damy T, Plante-Bordeneuve V, Coelho T, Mundayat R, Suhr OB, Waddington Cruz M, Rapezzi C; THAOS Investigators. Genotype and Phenotype of Transthyretin Cardiac Amyloidosis: THAOS (Transthyretin Amyloid Outcome Survey). J Am Coll Cardiol. 2016 Jul 12;68(2):161-72. doi: 10.1016/j.jacc.2016.03.596.
  PMID: 27386769
  citation: Sueyoshi T, Ueda M, Jono H, Irie H, Sei A, Ide J, Ando Y, Mizuta H. Wild-type transthyretin-derived amyloidosis in various ligaments and tendons. Hum Pathol. 2011 Sep;42(9):1259-64. doi: 10.1016/j.humpath.2010.11.017. Epub 2011 Feb 21.
  PMID: 21334722
  citation: Garcia-Pavia P, Rapezzi C, Adler Y, Arad M, Basso C, Brucato A, Burazor I, Caforio ALP, Damy T, Eriksson U, Fontana M, Gillmore JD, Gonzalez-Lopez E, Grogan M, Heymans S, Imazio M, Kindermann I, Kristen AV, Maurer MS, Merlini G, Pantazis A, Pankuweit S, Rigopoulos AG, Linhart A. Diagnosis and treatment of cardiac amyloidosis. A position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur J Heart Fail. 2021 Apr;23(4):512-526. doi: 10.1002/ejhf.2140. Epub 2021 Apr 7.
  PMID: 33826207
  citation: Kittleson MM, Maurer MS, Ambardekar AV, Bullock-Palmer RP, Chang PP, Eisen HJ, Nair AP, Nativi-Nicolau J, Ruberg FL; American Heart Association Heart Failure and Transplantation Committee of the Council on Clinical Cardiology. Cardiac Amyloidosis: Evolving Diagnosis and Management: A Scientific Statement From the American Heart Association. Circulation. 2020 Jul 7;142(1):e7-e22. doi: 10.1161/CIR.0000000000000792. Epub 2020 Jun 1. Erratum In: Circulation. 2021 Jul 6;144(1):e10. Circulation. 2021 Jul 6;144(1):e11.
  PMID: 32476490
  citation: Rapezzi C, Aimo A, Serenelli M, Barison A, Vergaro G, Passino C, Panichella G, Sinagra G, Merlo M, Fontana M, Gillmore J, Quarta CC, Maurer MS, Kittleson MM, Garcia-Pavia P, Emdin M. Critical Comparison of Documents From Scientific Societies on Cardiac Amyloidosis: JACC State-of-the-Art Review. J Am Coll Cardiol. 2022 Apr 5;79(13):1288-1303. doi: 10.1016/j.jacc.2022.01.036.
  PMID: 35361352
  citation: Nativi-Nicolau J, Siu A, Dispenzieri A, Maurer MS, Rapezzi C, Kristen AV, Garcia-Pavia P, LoRusso S, Waddington-Cruz M, Lairez O, Witteles R, Chapman D, Amass L, Grogan M; THAOS Investigators. Temporal Trends of Wild-Type Transthyretin Amyloid Cardiomyopathy in the Transthyretin Amyloidosis Outcomes Survey. JACC CardioOncol. 2021 Oct 19;3(4):537-546. doi: 10.1016/j.jaccao.2021.08.009. eCollection 2021 Oct.
  PMID: 34729526
  citation: Maurer MS, Elliott P, Comenzo R, Semigran M, Rapezzi C. Addressing Common Questions Encountered in the Diagnosis and Management of Cardiac Amyloidosis. Circulation. 2017 Apr 4;135(14):1357-1377. doi: 10.1161/CIRCULATIONAHA.116.024438.
  PMID: 28373528
  citation: Lane T, Fontana M, Martinez-Naharro A, Quarta CC, Whelan CJ, Petrie A, Rowczenio DM, Gilbertson JA, Hutt DF, Rezk T, Strehina SG, Caringal-Galima J, Manwani R, Sharpley FA, Wechalekar AD, Lachmann HJ, Mahmood S, Sachchithanantham S, Drage EPS, Jenner HD, McDonald R, Bertolli O, Calleja A, Hawkins PN, Gillmore JD. Natural History, Quality of Life, and Outcome in Cardiac Transthyretin Amyloidosis. Circulation. 2019 Jul 2;140(1):16-26. doi: 10.1161/CIRCULATIONAHA.118.038169. Epub 2019 May 21. Erratum In: Circulation. 2019 Jul 30;140(5):e185.
  PMID: 31109193
  citation: Rubin J, Maurer MS. Cardiac Amyloidosis: Overlooked, Underappreciated, and Treatable. Annu Rev Med. 2020 Jan 27;71:203-219. doi: 10.1146/annurev-med-052918-020140.
  PMID: 31986086
  citation: Gillmore JD, Maurer MS, Falk RH, Merlini G, Damy T, Dispenzieri A, Wechalekar AD, Berk JL, Quarta CC, Grogan M, Lachmann HJ, Bokhari S, Castano A, Dorbala S, Johnson GB, Glaudemans AW, Rezk T, Fontana M, Palladini G, Milani P, Guidalotti PL, Flatman K, Lane T, Vonberg FW, Whelan CJ, Moon JC, Ruberg FL, Miller EJ, Hutt DF, Hazenberg BP, Rapezzi C, Hawkins PN. Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis. Circulation. 2016 Jun 14;133(24):2404-12. doi: 10.1161/CIRCULATIONAHA.116.021612. Epub 2016 Apr 22.
  PMID: 27143678
  citation: Vrana JA, Gamez JD, Madden BJ, Theis JD, Bergen HR 3rd, Dogan A. Classification of amyloidosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimens. Blood. 2009 Dec 3;114(24):4957-9. doi: 10.1182/blood-2009-07-230722. Epub 2009 Oct 1.
  PMID: 19797517
  citation: Campanella G, Hanna MG, Geneslaw L, Miraflor A, Werneck Krauss Silva V, Busam KJ, Brogi E, Reuter VE, Klimstra DS, Fuchs TJ. Clinical-grade computational pathology using weakly supervised deep learning on whole slide images. Nat Med. 2019 Aug;25(8):1301-1309. doi: 10.1038/s41591-019-0508-1. Epub 2019 Jul 15.
  PMID: 31308507
  citation: Miller AB, Januzzi JL, O'Neill BJ, Gundapaneni B, Patterson TA, Sultan MB, Lopez-Sendon J. Causes of Cardiovascular Hospitalization and Death in Patients With Transthyretin Amyloid Cardiomyopathy (from the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial [ATTR-ACT]). Am J Cardiol. 2021 Jun 1;148:146-150. doi: 10.1016/j.amjcard.2021.02.035. Epub 2021 Mar 3.
  PMID: 33667442
  citation: Kubo SH, Schulman S, Starling RC, Jessup M, Wentworth D, Burkhoff D. Development and validation of a patient questionnaire to determine New York Heart Association classification. J Card Fail. 2004 Jun;10(3):228-35. doi: 10.1016/j.cardfail.2003.10.005.
  PMID: 15190533
  citation: ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med. 2002 Jul 1;166(1):111-7. doi: 10.1164/ajrccm.166.1.at1102. No abstract available. Erratum In: Am J Respir Crit Care Med. 2016 May 15;193(10):1185.
  PMID: 12091180
  citation: Guralnik JM, Simonsick EM, Ferrucci L, Glynn RJ, Berkman LF, Blazer DG, Scherr PA, Wallace RB. A short physical performance battery assessing lower extremity function: association with self-reported disability and prediction of mortality and nursing home admission. J Gerontol. 1994 Mar;49(2):M85-94. doi: 10.1093/geronj/49.2.m85.
  PMID: 8126356
  citation: Carroll JD, Gaasch WH, McAdam KP. Amyloid cardiomyopathy: characterization by a distinctive voltage/mass relation. Am J Cardiol. 1982 Jan;49(1):9-13. doi: 10.1016/0002-9149(82)90270-3.
  PMID: 6459025
  citation: Amundsen BH, Helle-Valle T, Edvardsen T, Torp H, Crosby J, Lyseggen E, Stoylen A, Ihlen H, Lima JA, Smiseth OA, Slordahl SA. Noninvasive myocardial strain measurement by speckle tracking echocardiography: validation against sonomicrometry and tagged magnetic resonance imaging. J Am Coll Cardiol. 2006 Feb 21;47(4):789-93. doi: 10.1016/j.jacc.2005.10.040. Epub 2006 Jan 26.
  PMID: 16487846
  citation: Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, Flachskampf FA, Foster E, Goldstein SA, Kuznetsova T, Lancellotti P, Muraru D, Picard MH, Rietzschel ER, Rudski L, Spencer KT, Tsang W, Voigt JU. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging. 2015 Mar;16(3):233-70. doi: 10.1093/ehjci/jev014. Erratum In: Eur Heart J Cardiovasc Imaging. 2016 Apr;17(4):412. Eur Heart J Cardiovasc Imaging. 2016 Sep;17 (9):969.
  PMID: 25712077
  citation: Devereux RB, Alonso DR, Lutas EM, Gottlieb GJ, Campo E, Sachs I, Reichek N. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol. 1986 Feb 15;57(6):450-8. doi: 10.1016/0002-9149(86)90771-x.
  PMID: 2936235
  citation: Mor-Avi V, Sugeng L, Weinert L, MacEneaney P, Caiani EG, Koch R, Salgo IS, Lang RM. Fast measurement of left ventricular mass with real-time three-dimensional echocardiography: comparison with magnetic resonance imaging. Circulation. 2004 Sep 28;110(13):1814-8. doi: 10.1161/01.CIR.0000142670.65971.5F. Epub 2004 Sep 20.
  PMID: 15381653
  citation: Takeuchi M, Nishikage T, Mor-Avi V, Sugeng L, Weinert L, Nakai H, Salgo IS, Gerard O, Lang RM. Measurement of left ventricular mass by real-time three-dimensional echocardiography: validation against magnetic resonance and comparison with two-dimensional and m-mode measurements. J Am Soc Echocardiogr. 2008 Sep;21(9):1001-5. doi: 10.1016/j.echo.2008.07.008.
  PMID: 18765176
  citation: Tendler A, Helmke S, Teruya S, Alvarez J, Maurer MS. The myocardial contraction fraction is superior to ejection fraction in predicting survival in patients with AL cardiac amyloidosis. Amyloid. 2015 Mar;22(1):61-6. doi: 10.3109/13506129.2014.994202. Epub 2014 Dec 16.
  PMID: 25510353
  citation: Bokhari S, Castano A, Pozniakoff T, Deslisle S, Latif F, Maurer MS. (99m)Tc-pyrophosphate scintigraphy for differentiating light-chain cardiac amyloidosis from the transthyretin-related familial and senile cardiac amyloidoses. Circ Cardiovasc Imaging. 2013 Mar 1;6(2):195-201. doi: 10.1161/CIRCIMAGING.112.000132. Epub 2013 Feb 11.
  PMID: 23400849
  citation: Cheng RK, Levy WC, Vasbinder A, Teruya S, De Los Santos J, Leedy D, Maurer MS. Diuretic Dose and NYHA Functional Class Are Independent Predictors of Mortality in Patients With Transthyretin Cardiac Amyloidosis. JACC CardioOncol. 2020 Sep;2(3):414-424. doi: 10.1016/j.jaccao.2020.06.007. Epub 2020 Sep 15.
  PMID: 33073249
  citation: Lee JY, Moon SH, Suh BK, Yang MH, Park MS. Outcome and Complications in Surgical Treatment of Lumbar Stenosis or Spondylolisthesis in Geriatric Patients. Yonsei Med J. 2015 Sep;56(5):1199-205. doi: 10.3349/ymj.2015.56.5.1199.
  PMID: 26256960
  citation: Kazi DS, Bellows BK, Baron SJ, Shen C, Cohen DJ, Spertus JA, Yeh RW, Arnold SV, Sperry BW, Maurer MS, Shah SJ. Cost-Effectiveness of Tafamidis Therapy for Transthyretin Amyloid Cardiomyopathy. Circulation. 2020 Apr 14;141(15):1214-1224. doi: 10.1161/CIRCULATIONAHA.119.045093. Epub 2020 Feb 12.
  PMID: 32078382
  citation: Ruiz-Negron N, Nativi-Nicolau J, Maurer MS, Moran AE, Kovacsovics T, Bellows BK. Cost-effectiveness of technetium pyrophosphate scintigraphy versus heart biopsy for the diagnosis of transthyretin amyloidosis. Amyloid. 2019;26(sup1):71-72. doi: 10.1080/13506129.2019.1583192. No abstract available.
  PMID: 31343305
  citation: Weintraub WS, Bhatt DL, Zhang Z, Dolman S, Boden WE, Bress AP, King JB, Bellows BK, Tajeu GS, Derington CG, Johnson J, Andrade K, Steg PG, Miller M, Brinton EA, Jacobson TA, Tardif JC, Ballantyne CM, Kolm P. Cost-effectiveness of Icosapent Ethyl for High-risk Patients With Hypertriglyceridemia Despite Statin Treatment. JAMA Netw Open. 2022 Feb 1;5(2):e2148172. doi: 10.1001/jamanetworkopen.2021.48172.
  PMID: 35157055
  citation: Zhang Z, Kolm P, Grau-Sepulveda MV, Ponirakis A, O'Brien SM, Klein LW, Shaw RE, McKay C, Shahian DM, Grover FL, Mayer JE, Garratt KN, Hlatky M, Edwards FH, Weintraub WS. Cost-effectiveness of revascularization strategies: the ASCERT study. J Am Coll Cardiol. 2015 Jan 6;65(1):1-11. doi: 10.1016/j.jacc.2014.09.078.
  PMID: 25572503
  citation: Zhang Z, Kolm P, Boden WE, Hartigan PM, Maron DJ, Spertus JA, O'Rourke RA, Shaw LJ, Sedlis SP, Mancini GB, Berman DS, Dada M, Teo KK, Weintraub WS. The cost-effectiveness of percutaneous coronary intervention as a function of angina severity in patients with stable angina. Circ Cardiovasc Qual Outcomes. 2011 Mar;4(2):172-82. doi: 10.1161/CIRCOUTCOMES.110.940502. Epub 2011 Feb 8.
  PMID: 21304091
  responsible party type: Principal Investigator
  investigator affiliation: Columbia University
  investigator full name: Mathew S. Maurer, MD
  investigator title: Arnold and Arlene Goldstein Professor of Cardiology (in Medicine, Dept of Medicine Cardiology)
  mesh term: Spinal Stenosis
  mesh term: Cardiomyopathies
  mesh term: Cardiomyopathy, Hypertrophic
  mesh term: Amyloidosis
  mesh term: Constriction, Pathologic
  sharing ipd: Undecided